Core Viewpoint - Changchun High-tech's stock has experienced a decline in recent trading sessions, with significant net outflows of capital and a decrease in both revenue and net profit year-on-year [1][2]. Financial Performance - For the period from January to September 2025, Changchun High-tech reported operating revenue of 9.807 billion yuan, a year-on-year decrease of 5.60% [2]. - The net profit attributable to shareholders was 1.165 billion yuan, reflecting a substantial year-on-year decline of 58.23% [2]. Stock Market Activity - On November 21, Changchun High-tech's stock price fell by 2.01%, trading at 99.65 yuan per share, with a total market capitalization of 40.651 billion yuan [1]. - The stock has seen a year-to-date increase of 2.86%, but has declined by 4.69% over the last five trading days and 15.44% over the last 20 days [1]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 4.63% to 104,100, while the average number of circulating shares per person increased by 4.85% to 3,840 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited being the third-largest shareholder, increasing its holdings by 1.307 million shares [3]. Dividend Distribution - Since its A-share listing, Changchun High-tech has distributed a total of 4.791 billion yuan in dividends, with 3.259 billion yuan distributed over the past three years [3].

Core Points - Boda Pharmaceutical's stock price decreased by 2.08% on November 21, reaching 49.06 CNY per share, with a market capitalization of 20.641 billion CNY [1] - The company has experienced a year-to-date stock price decline of 8.69%, with a 9.68% drop over the last five trading days and a 23.44% decline over the past 60 days [1] - As of September 30, 2025, Boda Pharmaceutical reported a revenue of 2.717 billion CNY, a year-on-year increase of 15.90%, while the net profit attributable to shareholders decreased by 23.86% to 317 million CNY [2] Financial Performance - The company has distributed a total of 669 million CNY in dividends since its A-share listing, with 184 million CNY distributed over the last three years [3] - As of September 30, 2025, the number of shareholders decreased by 7.99% to 29,500, while the average number of circulating shares per person increased by 8.68% to 14,198 shares [2] Shareholder Structure - Among the top ten circulating shareholders, Xingshan Commercial Model Mixed Fund A is the fifth largest with 5.827 million shares, marking a new entry [3] - E Fund's Growth Enterprise Board ETF, ranked sixth, reduced its holdings by 912,300 shares to 5.456 million shares [3] - Xingshan Helun Mixed Fund A is the seventh largest shareholder with 5.402 million shares, also a new entry [3]

11月19日，西藏药业盘中下跌2.00%，截至13:24，报44.55元/股，成交1.05亿元，换手率0.72%，总市值 143.59亿元。 西藏药业所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：疫苗、创新药、生 物医药、医疗器械、中药等。 截至9月30日，西藏药业股东户数4.54万，较上期增加0.57%；人均流通股7092股，较上期减少0.57%。 2025年1月-9月，西藏药业实现营业收入20.89亿元，同比减少3.96%；归母净利润7.22亿元，同比减少 8.85%。 分红方面，西藏药业A股上市后累计派现22.58亿元。近三年，累计派现15.80亿元。 机构持仓方面，截止2025年9月30日，西藏药业十大流通股东中，香港中央结算有限公司位居第七大流 通股东，持股365.85万股，相比上期增加106.82万股。创新药（159992）位居第九大流通股东，持股 158.17万股，为新进股东。南方中证1000ETF（512100）位居第十大流通股东，持股147.59万股，为新 进股东。华夏行业景气混合A（003567）退出十大流通股东之列。 责任编辑：小浪快报 资金流向方面，主力资金净流出 ...

资料显示，浙江亨通控股股份有限公司位于浙江省湖州市德清县玉屏路地理信息小镇C15幢，成立日期 1999年5月11日，上市日期1999年11月16日，公司主营业务涉及生物农药、兽药、饲料添加剂产品的生 产与销售、热电联供等相关业务。主营业务收入构成为：电解铜箔67.62%，电与蒸汽16.17%，兽药 16.14%，其他业务0.06%。 11月19日，亨通股份盘中下跌2.05%，截至10:08，报4.30元/股，成交6917.87万元，换手率0.53%，总市 值127.90亿元。 资金流向方面，主力资金净流出922.92万元，特大单买入623.93万元，占比9.02%，卖出1031.25万元， 占比14.91%；大单买入1713.06万元，占比24.76%，卖出2228.67万元，占比32.22%。 亨通股份今年以来股价涨68.63%，近5个交易日涨1.18%，近20日跌5.49%，近60日涨35.65%。 今年以来亨通股份已经1次登上龙虎榜，最近一次登上龙虎榜为8月29日，当日龙虎榜净买入4805.76万 元；买入总计1.46亿元 ，占总成交额比22.97%；卖出总计9786.16万元 ，占总成交额比15.40 ...

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 182.83%, but a recent decline in the last 20 and 60 days, indicating potential market concerns [1][2]. Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002, with its IPO on November 16, 2017. The company focuses on the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals [1]. - The main revenue composition includes children's medicine (61.12%), chronic disease medicine (22.71%), and others (16.17%) [1]. Financial Performance - For the period from January to September 2025, Yipinhong reported operating revenue of 814 million yuan, a year-on-year decrease of 34.35%. The net profit attributable to the parent company was -136 million yuan, an increase of 44.80% year-on-year [2]. - Since its A-share listing, Yipinhong has distributed a total of 335 million yuan in dividends, with 151 million yuan distributed over the past three years [3]. Shareholder Information - As of October 31, 2025, Yipinhong had 20,700 shareholders, an increase of 9.42% from the previous period. The average circulating shares per person decreased by 8.61% to 20,156 shares [2]. - Notable new institutional shareholders include Hong Kong Central Clearing Limited, holding 4.1496 million shares, and several other funds entering the top ten circulating shareholders [3]. Market Activity - On November 19, Yipinhong's stock price fell by 2.01% to 48.25 yuan per share, with a trading volume of approximately 49.77 million yuan and a turnover rate of 0.24%. The total market capitalization is 21.794 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.576 million yuan [1].

机构持仓方面，截止2025年9月30日，西藏药业十大流通股东中，香港中央结算有限公司位居第七大流 通股东，持股365.85万股，相比上期增加106.82万股。创新药（159992）位居第九大流通股东，持股 158.17万股，为新进股东。南方中证1000ETF（512100）位居第十大流通股东，持股147.59万股，为新 进股东。华夏行业景气混合A（003567）退出十大流通股东之列。 责任编辑：小浪快报 资金流向方面，主力资金净流出1588.49万元，特大单买入0.00元，占比0.00%，卖出140.46万元，占比 1.19%；大单买入1668.74万元，占比14.15%，卖出3116.77万元，占比26.44%。 截至9月30日，西藏药业股东户数4.54万，较上期增加0.57%；人均流通股7092股，较上期减少0.57%。 2025年1月-9月，西藏药业实现营业收入20.89亿元，同比减少3.96%；归母净利润7.22亿元，同比减少 8.85%。 分红方面，西藏药业A股上市后累计派现22.58亿元。近三年，累计派现15.80亿元。 11月18日，西藏药业盘中下跌2.01%，截至13:01，报45.28元/股 ...

Core Viewpoint - Jinlei Co., Ltd. has experienced a stock price increase of 33.27% year-to-date, but has seen a decline of 7.81% in the last five trading days, indicating volatility in its stock performance [2]. Company Overview - Jinlei Co., Ltd. is located in Jinan, Shandong Province, established on March 24, 2006, and listed on April 22, 2015. The company specializes in the research, production, and sales of wind turbine main shafts and various large castings and forgings [2]. - The main revenue composition includes: wind power shafts (forged and cast) 67.80%, other precision shafts 14.19%, assembly business 10.71%, and others 7.30% [2]. Financial Performance - For the period from January to September 2025, Jinlei Co., Ltd. achieved operating revenue of 2.119 billion yuan, representing a year-on-year growth of 61.35%. The net profit attributable to shareholders was 305 million yuan, reflecting a year-on-year increase of 104.59% [2]. - Since its A-share listing, Jinlei Co., Ltd. has distributed a total of 506 million yuan in dividends, with 210 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Jinlei Co., Ltd. was 27,900, a decrease of 7.27% from the previous period. The average circulating shares per person increased by 7.84% to 8,701 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the third-largest shareholder with 4.2502 million shares, an increase of 1.0937 million shares from the previous period. The Southern CSI 1000 ETF is a new entrant in the top ten, holding 2.0467 million shares [3].

11月17日，温氏股份盘中下跌2.05%，截至09:55，报17.69元/股，成交2.44亿元，换手率0.23%，总市值 1177.08亿元。 分红方面，温氏股份A股上市后累计派现301.10亿元。近三年，累计派现69.35亿元。 资金流向方面，主力资金净流出1149.53万元，特大单买入702.43万元，占比2.88%，卖出1445.23万元， 占比5.93%；大单买入4298.48万元，占比17.63%，卖出4705.21万元，占比19.30%。 机构持仓方面，截止2025年9月30日，温氏股份十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股1.44亿股，相比上期增加550.13万股。易方达创业板ETF（159915）位居第九大流通股 东，持股1.13亿股，相比上期减少1909.10万股。 温氏股份今年以来股价涨10.48%，近5个交易日跌3.33%，近20日跌2.27%，近60日涨3.39%。 责任编辑：小浪快报 资料显示，温氏食品集团股份有限公司位于广东省云浮市新兴县新城镇东堤北路9号，成立日期1993年7 月26日，上市日期2015年11月2日，公司主营业务涉及肉鸡和肉猪养殖及其产品销 ...

Company Overview - KQ Bio, established on January 11, 2001, and listed on September 22, 2020, is located in Wuhan, Hubei Province. The company specializes in the research, production, and sales of veterinary biological products and animal epidemic prevention technology services [1][2]. - The main business revenue composition includes 94.64% from veterinary biological products, 4.46% from other sources, and 0.90% from supplementary services [1]. Financial Performance - For the period from January to September 2025, KQ Bio achieved a revenue of 738 million yuan, representing a year-on-year growth of 10.87%. The net profit attributable to the parent company was 338 million yuan, showing a year-on-year increase of 29.62% [2]. - Cumulative cash dividends since the A-share listing amount to 711 million yuan, with 488 million yuan distributed over the past three years [3]. Stock Performance - As of November 17, KQ Bio's stock price was 16.24 yuan per share, with a market capitalization of 7.57 billion yuan. The stock has increased by 17.15% year-to-date but has seen a decline of 0.43% over the last five trading days, 6.13% over the last 20 days, and 5.80% over the last 60 days [1]. - The number of shareholders as of September 30 was 9,713, an increase of 2.41% from the previous period, while the average circulating shares per person decreased by 2.36% to 47,990 shares [2]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the ninth largest circulating shareholder, holding 5.5731 million shares, an increase of 3.2155 million shares from the previous period [3].

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 207.74%, but recent trends indicate a decline over the past 60 days [1][2]. Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002. It was listed on November 16, 2017. The company focuses on the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals [1]. - The main revenue composition includes children's medicine (61.12%), chronic disease medicine (22.71%), and others (16.17%) [1]. Financial Performance - For the period from January to September 2025, Yipinhong reported an operating income of 814 million yuan, a year-on-year decrease of 34.35%. The net profit attributable to the parent company was -136 million yuan, an increase of 44.80% year-on-year [2]. - Since its A-share listing, Yipinhong has distributed a total of 335 million yuan in dividends, with 151 million yuan distributed over the past three years [3]. Shareholder Information - As of October 31, 2025, Yipinhong had 20,700 shareholders, an increase of 9.42% from the previous period. The average circulating shares per person decreased by 8.61% to 20,156 shares [2]. - Notable new shareholders include Hong Kong Central Clearing Limited, holding 4.1496 million shares, and several mutual funds entering the top ten circulating shareholders [3]. Market Activity - On November 14, Yipinhong's stock rose by 2.02%, reaching 52.50 yuan per share, with a trading volume of 165 million yuan and a turnover rate of 0.77%. The total market capitalization is 23.714 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.576 million yuan [1].